With the revised Act on the Safety and Support of Advanced Regenerative Medicine and Advanced Biopharmaceuticals (Advanced Regenerative Medicine Act) having come into full effect this February, Seoul Yes Bio—which is currently engaged in research, development, and business operations related to advanced regenerative medicine—is accelerating its R&D efforts.

Seoul Yes Bio announced on the 9th that it completed the domestic patent registration in February for its “Cartilage Cultivation System Using Biomaterials for Tissue Repair,” which was filed in July of last year. Seoul Yes Bio and Seoul Yes Hospital jointly filed and registered this patent.

The newly registered patent for the “Cartilage Cultivation System Using Biomaterials for Tissue Repair” is a technology that enables effective cartilage regeneration by harvesting a patient’s cartilage tissue with minimal invasiveness, culturing and proliferating it, and then transplanting it into the patient’s damaged cartilage site. It is expected to significantly aid in the regeneration of damaged cartilage tissue in patients with knee osteoarthritis when applied clinically.

Since its founding, Seoul Yes Bio has been at the forefront of developing cell therapies for advanced regenerative medicine clinical research and treatment, and has previously filed three patents related to bone marrow stem cell culture for the treatment of cartilage regeneration and arthritis.

Kim Song-shin, CEO of Seoul Yes Bio, stated, “We expect the technology for which we have now completed patent registration to demonstrate efficacy in treating arthritis and related diseases through combination therapy with our existing stem cell treatments,” adding, “We plan to not only validate the therapeutic efficacy of this technology through advanced regenerative medicine clinical research but also develop it into a therapeutic agent.”

Meanwhile, Seoul Yes Bio is a cell therapy R&D company established with investment from Seoul Yes Hospital to conduct advanced regenerative medicine clinical research and treatment operations. In line with the revision of the Advanced Regenerative Medicine Act, the company plans to conduct advanced regenerative medicine clinical research jointly with Seoul Yes Hospital by 2025, based on the cell therapies it has developed to date.